Amphastar Pharmaceuticals, Inc.
AMPH · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Revenue | $191,840 | $174,414 | $170,528 | $186,523 |
| % Growth | 10% | 2.3% | -8.6% | – |
| Cost of Goods Sold | $93,194 | $87,924 | $85,277 | $99,875 |
| Gross Profit | $98,646 | $86,490 | $85,251 | $86,648 |
| % Margin | 51.4% | 49.6% | 50% | 46.5% |
| R&D Expenses | $22,354 | $20,080 | $20,096 | $18,142 |
| G&A Expenses | $39,467 | $13,991 | $15,996 | $12,938 |
| SG&A Expenses | $50,972 | $24,226 | $27,862 | $23,362 |
| Sales & Mktg Exp. | $11,505 | $10,235 | $11,866 | $10,424 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $73,326 | $44,306 | $47,958 | $41,504 |
| Operating Income | $25,320 | $42,184 | $37,293 | $45,144 |
| % Margin | 13.2% | 24.2% | 21.9% | 24.2% |
| Other Income/Exp. Net | -$3,807 | -$2,849 | -$6,431 | -$1,182 |
| Pre-Tax Income | $21,513 | $39,335 | $30,862 | $43,962 |
| Tax Expense | $4,163 | $8,305 | $5,577 | $5,998 |
| Net Income | $17,350 | $31,030 | $25,285 | $37,964 |
| % Margin | 9% | 17.8% | 14.8% | 20.4% |
| EPS | 0.38 | 0.66 | 0.53 | 0.78 |
| % Growth | -42.4% | 24.5% | -32.1% | – |
| EPS Diluted | 0.37 | 0.64 | 0.51 | 0.74 |
| Weighted Avg Shares Out | 46,474 | 46,949 | 47,641 | 48,429 |
| Weighted Avg Shares Out Dil | 47,677 | 48,128 | 49,890 | 52,058 |
| Supplemental Information | – | – | – | – |
| Interest Income | $2,246 | $1,921 | $2,089 | $2,292 |
| Interest Expense | $6,284 | $6,281 | $6,286 | $6,425 |
| Depreciation & Amortization | $14,129 | $16,239 | $15,207 | $14,664 |
| EBITDA | $41,926 | $61,855 | $52,355 | $65,051 |
| % Margin | 21.9% | 35.5% | 30.7% | 34.9% |